Alzheimer's Disease CausesScientists believe that a build-up of two abnormal structures in the brain play a role in Alzheimer's. Learn about amyloid plaques and neurofib...
- Auto Immune Conditions
- Bladder & Kidney Health
- Brain & Nervous System
- Care Transitions
- Dental Health
- Emotional Health
- Eye Health
- Falls Prevention
- Financial Planning
- General Safety
- Health Care Basics
- Healthy Living
- Hearing Loss
- Heart Health
- High Blood Pressure
- Life Transitions
- Lung Health
- Men's Health
- Nutrition & Weight Management
- Pain Management
- Preventive Health
- Sexual Health
- Stomach & Digestive Health
- Stress & Anxiety
- Women's Health
While much progress has been made in Alzheimer’s disease (AD) research, the exact cause is unknown. However, many scientists believe that a build-up of two abnormal structures in the brain play an important role. These structures are called amyloid plaques and neurofibrillary tangles.
Amyloid plaques (pronounced: AM-uh-loyd plaks) are dense, mostly insoluble clumps of protein fragments. They deposit a highly damaging substance outside and around the brain’s nerve cells.
People with AD have a lot of these plaques in their hippocampus. The hippocampus is involved with memory, including how immediate or short-term memories are stored into long-term memories.
Your ability to function in everyday life also can be affect by an unhealthy hippocampus. Everything you do involves your ability to acquire, store, and retrieve memories. This can be anything from remembering if you ate lunch to recognizing a loved one to recalling if you turned off the stove.
The hippocampus also is essential to both spatial memory and spatial navigation. Spatial memory is how you retain information about your surrounding. Spatial navigation involves how you travel to a destination. In fact, research suggests early hippocampus damage may explain why AD sufferers often wander and get lost.
Neurofibrillary tangles (pronounced NER-oh-FI-bri-lair-ee) are insoluble twisted up fibers that clog the brain from the inside-out.
Brain nerve cells (called neurons) have a special transport system called microtubules. It acts like railroad tracks, and safely guide and transport nutrients, molecules, and information to other cells. An important fiber-like protein called tau is responsible for keeping those microtubules stable.
However, the tau’s chemical make-up is altered in people with AD. This makes the threads of tau become tangled and twisted. Thus, the microtubules become unstable and disintegrate, which collapses the entire neuron transport system.
This series of events may be related to the first visible sign of AD—memory loss. That said, the scientific jury is still out as to whether or not amyloid plaques, tangles, and tau are a direct cause of AD. Instead, they may symptoms of AD progression or perhaps some combination thereof.
Researchers are certain of a genetic component to AD. In the elderly, the gene most associated with the onset of symptoms is located on chromosome 19. It is called apolipoprotein E (APOE).
There are several alleles (versions) of APOE. About 40 percent of people who develop AD later in life have an APOE e4 allele. A blood test can determine if you have it.
However, it’s still not possible to predict who will develop AD. Some people with one or even two APOE e4 alleles never develop the disease. Others who get AD don’t have any APOE e4 alleles. Still, an “AD gene” does increase your risk.
As of 2011, scientists have discovered five new genes—for a total of 10—that increase your AD risk. In fact, scientists now believe the predisposition to AD may be up to 80 percent genetic, though estimates vary.
One of these newly identified genes is CD33. It causes the body to not eliminate as many amyloid plaques as it should. And scientists have long believed amyloid plaques—and more specifically their building up to toxic levels—likely plays a key role in degradation of brain neurons.
Genetic studies of families with a history of early-onset AD have identified mutations in three different genes:
- APP (on chromosome 21)
- PSEN-1 (on chromosome 14)
- PSEN-2 (on chromosome 1)
These genes are thought to be responsible for the rare form of AD that afflicts men and women in their early 30s or 40s. They are believed to help produce amyloid protein, which forms amyloid plaques and are the hallmarks of AD. These mutated genes do not play a role in the more common late-onset AD.
Of note, less than one out every 1,000 cases of Alzheimer’s disease is the early-onset type. However, approximately 50 percent of people who have a parent with early-onset AD will likely inherit the genetic mutation and develop the disease.
For those young individuals where neither parent had early-onset AD, research has found that often a second-degree relative (e.g., an uncle, aunt, and/or grandparent) suffered from the condition.
Medically Reviewed by: Jennifer Monti, MPH, MD
Published: May 11, 2011
Last Updated: Jan 22, 2014
Published By: Healthline Networks, Inc.
- Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement.
- Alzheimer's Association. (2011). Press Release: New Criteria and Guidelines for the Diagnosis of Alzheimer's Disease Published for the first Time in 27 Years. The Alzheimer's Association, 1-11.
- Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004). Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol, 61(5), 661-666.
- Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer's disease. Lancet, 377(9770), 1019-1031.
- Bird, T. D. (2010). Early-Onset Familial Alzheimer Disease. University of Washington, Gene Review.
- Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev(1), CD003120.
- Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011). Possible implications of Insulin Resistance and Glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., & Bennett, D. A. (2010). Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry, 67(3), 304-310.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., James, B. D., & Bennett, D. A. (2010). Association between life space and risk of mortality in advanced age. J Am Geriatr Soc, 58(10), 1925-1930.
- Brinkley, T. E., Lovato, J. F., Arnold, A. M., Furberg, C. D., Kuller, L. H., Burke, G. L., et al. (2010). Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens, 23(5), 528-533.
- Daviglus, M. L., Bell, C. C., Berrettini, W., Bowen, P. E., Connolly, E. S., Cox, N. J., et al. (2010). NIH State-of-the-Science Conference Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH Consens State Sci Statements, 27(4).
- De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A, 106(6), 1971-1976.
- deIpolyi, A. R., Rankin, K. P., Mucke, L., Miller, B. L., & Gorno-Tempini, M. L. (2007). Spatial cognition and the human navigation network in AD and MCI. Neurology, 69(10), 986-997.
- DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300(19), 2253-2262.
- Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., et al. (2002). Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc, 77(7), 681-696.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet, 41(10), 1088-1093.
- Herrmann, W., & Obeid, R. (2011). Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med, 49(3), 435-441.
- Keating, D. J., Chen, C., & Pritchard, M. A. (2006). Alzheimer's disease and endocytic dysfunction: clues from the Down syndrome-related proteins, DSCR1 and ITSN1. Ageing Res Rev, 5(4), 388-401.
- Ladika, D. J., & Gurevitz, S. L. (2011). Identifying the most common causes of reversible dementias: a review. JAAPA, 24(3), 28-31, 57.
- Li, K., Dai, D., Zhao, B., Yao, L., Yao, S., Wang, B., et al. (2010). Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm, 117(1), 97-104.
- McKhanna, G. M., Knopmanc, D. S., Chertkowd, H., Hyman, B. T., Clifford R. Jack, J., Kawash, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup.Alzheimer’s & Dementia, 1–7.
- Nation, D. A., Hong, S., Jak, A. J., Delano-Wood, L., Mills, P. J., Bondi, M. W., et al. (2011). Stress, exercise, and Alzheimer's disease: A neurovascular pathway. Med Hypotheses.
- National Library of Medicine. (2011). Alzheimer's Disease. Medline Plus; U.S. National Library of Medicine; National Institutes of Health.
- NCCAM. (2011). National Center for Complementary and Alternative Medicine: The Ginkgo Evaluation of Memory (GEM) Study. National Institutes of Health' National Center for Complementary and Alternative Medicine.
- NIA. (2008). Alzheimer's Disease: Unraveling the Mystery. National Institute on Aging; National Institutes of Heath; US Department of Health and Human Services; NIH Publication Number 08-3782, 1-43.
- NIA. (2011). Caring for a Person with Alzheimer's Disease; Medicine Chart. National Institutes of Health; National Institute on Aging; Alzheimer's Disease Education & Referral Center.
- NINDS. (2010). NINDS Alzheimer's Disease Information Page. National Institute of Neurological Disorders and Stroke; National Institutes of Health; US Department of Health & Human Services.
- NINDS. (2011). Dementia: Hope Through Research. National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
- Panza, F., Frisardi, V., Imbimbo, B. P., D'Onofrio, G., Pietrarossa, G., Seripa, D., et al. (2010). Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2(6), 767-782.
- Redish, A. D. (2001). The hippocampal debate: are we asking the right questions? Behav Brain Res, 127(1-2), 81-98.
- Reitz, C., Brayne, C., & Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nat Rev Neurol, 7(3), 137-152.
- Reitz, C., den Heijer, T., van Duijn, C., Hofman, A., & Breteler, M. M. (2007). Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology, 69(10), 998-1005.
- Seneff, S., Wainwright, G., & Mascitelli, L. (2011). Nutrition and Alzheimer's disease: The detrimental role of a high carbohydrate diet.Eur J Intern Med, 22(2), 134-140.
- Snitz, B. E., O'Meara, E. S., Carlson, M. C., Arnold, A. M., Ives, D. G., Rapp, S. R., et al. (2009). Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA, 302(24), 2663-2670.
- Solomon, P. R., Adams, F., Silver, A., Zimmer, J., & DeVeaux, R. (2002). Ginkgo for memory enhancement: a randomized controlled trial. JAMA, 288(7), 835-840.
- Traykov, L., Rigaud, A. S., Cesaro, P., & Boller, F. (2007). [Neuropsychological impairment in the early Alzheimer's disease].Encephale, 33(3 Pt 1), 310-316.
- Uc, E. Y., Rizzo, M., Anderson, S. W., Shi, Q., & Dawson, J. D. (2004). Driver route-following and safety errors in early Alzheimer disease.Neurology, 63(5), 832-837.
- Wegiel, J., Gong, C. X., & Hwang, Y. W. (2011). The role of DYRK1A in neurodegenerative diseases. FEBS J, 278(2), 236-245.
- Wilson, R. S., Mendes De Leon, C. F., Barnes, L. L., Schneider, J. A., Bienias, J. L., Evans, D. A., et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287(6), 742-748.
- Yu, F. (2011). Guiding Research and Practice: A Conceptual Model for Aerobic Exercise Training in Alzheimer's Disease. Am J Alzheimers Dis Other Demen.